If you follow peptides at all, you’ve seen the headlines: “Peptides are becoming legal in 2026.” The reality is more specific, and a lot more cautious, than those headlines suggest. Something genuinely did change in 2026 - but what changed is a procedural step, not a green light. This page walks through exactly what happened, in order, and what it does and doesn’t mean for access.
What actually happened, in order
The current story has a clear timeline, and the dates matter because each step does something different.
September 2023. The FDA placed 19 widely used peptides into Category 2 of its Section 503A bulk drug substances list - the category reserved for substances the agency has determined raise significant safety concerns. In practical terms, that designation kept licensed compounding pharmacies from preparing those peptides for patients.
February 27, 2026. Health and Human Services Secretary Robert F. Kennedy Jr. discussed peptides publicly during a podcast appearance, saying he expected the FDA to act “within a couple of weeks” to make roughly 14 of these peptides more accessible through lawful channels, and criticizing how the prior administration had handled the 2023 designations. This was a signal of policy direction - not a rule, not a legal change, and not binding on anyone.
April 15, 2026. This was the formal step. The FDA published a notice with two parts. First, it announced it would remove 12 peptide bulk substances from Category 2 within seven calendar days, on the basis that the original nominators had withdrawn their nominations. Second, it scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for July 23-24, 2026 to consider whether some of those peptides should be added to the list pharmacies can actually compound from.
April 22, 2026. The Category 2 removals took effect.
That’s the whole event so far. Notice what is missing: at no point in 2026 has the FDA placed any of these peptides into Category 1 - the list that authorizes compounding. The popular shorthand that “peptides moved from Category 2 to Category 1” is not what happened.
The 12 peptides that came off Category 2
The substances removed from Category 2 effective April 22, 2026 are:
- BPC-157
- TB-500 (a thymosin beta-4 fragment)
- MOTS-c
- KPV
- Semax
- Epitalon
- Emideltide (DSIP)
- LL-37 (Cathelicidin)
- DiHexa (dihexa acetate)
- PEG-MGF
- Melanotan II
- GHK-Cu (injectable form)
One technical detail worth understanding: the FDA evaluates these substances by their exact chemical form. A peptide nominated as an acetate salt is treated as a different entry from its free-base form. That’s why the official agenda lists items like “BPC-157 (free base) / BPC-157 acetate” separately. It’s a small point, but it’s the kind of distinction that determines whether a future authorization actually covers the version a pharmacy would use.
What “removal from Category 2” does and doesn’t mean
This is the crux of the page, and where most coverage goes wrong.
Category 2 is the “significant safety concerns” bucket. Being removed from it means the substance is no longer formally flagged as raising those concerns. It does not mean the substance moved to Category 1 (“may be compounded”). It also doesn’t mean the FDA reviewed new safety data and changed its mind - the removals happened because the nominations were withdrawn, a procedural event, not a safety clearance.
So where do the 12 peptides sit now? In a gap. They are neither on the prohibited list nor on the permitted list. Several major pharmacy-law firms reviewing the action for their clients reached the same conclusion and advised compounding pharmacies not to treat the April removal as authorization to start preparing these peptides. The mechanics of how the 503A and 503B bulks lists work - and why a substance has to be affirmatively on a list, not merely off another one - are covered in detail on our 503A vs 503B page.
Note: “Not prohibited” and “permitted” are not the same thing in compounding law. A bulk substance generally needs an affirmative basis - a USP monograph, a component of an FDA-approved drug, or a place on the 503A bulks list - before a pharmacy can compound with it. For peptides like BPC-157 and Semax, none of the first two apply, which is why the bulks list is the pathway that matters.
The July 23-24, 2026 PCAC meeting - now decided
The advisory committee meeting has since taken place, and the results landed almost exactly along the fault line this page described. The committee reviewed seven of the 12 peptides and recommended six of them for the 503A bulks list - BPC-157, KPV, and TB-500 (each 8-6 with one abstention), MOTS-c (7-5, two abstentions), and Semax and Epitalon by similarly narrow margins on day two. Emideltide (DSIP) was rejected, 7-6. Notably, the committee reached those conclusions over the objection of FDA’s own review scientists, who had recommended against all seven. The full results, vote counts, and what happens next are covered in our PCAC vote results page.
The remaining five peptides - LL-37, DiHexa, PEG-MGF, Melanotan II, and injectable GHK-Cu - were not put on the July agenda. They’re slated for a later review, expected by around February 2027, with the injectable GHK-Cu following a somewhat separate evaluation track.
A few things about the committee are easy to misread:
- The vote is advisory, not binding. PCAC recommends; the FDA decides. Historically the agency gives PCAC recommendations real weight, but it is not obligated to follow them.
- A favorable vote does not place anything on the bulks list. It initiates the formal rulemaking pipeline that could add a substance. Rulemaking takes time - typically far longer than the meeting itself.
- The “uses evaluated” on the agenda are not endorsements. They reflect the evidence packages the FDA reviewed as part of the nomination, not the agency’s blessing of those uses.
Why this isn’t legal compounding access - yet
Putting it plainly: the legal status of these peptides has not changed - even after the July votes. Compounding them sits outside the FDA’s enforcement framework both before and after the meeting, and stays that way until the agency publishes a final rule through the ordinary rulemaking process.
With the committee’s favorable votes on six peptides now in hand, everything rides on whether the FDA follows through with rulemaking - proposed rule, public comment, final rule. There is no deadline on that process, prior bulks-list rulemaking has taken over two years, and the agency’s own scientists are on record opposing all seven substances - so a realistic earliest window is late 2027 or beyond, and that assumes everything breaks in that direction, which is not certain. There is one statutory wild card: the law allows the HHS Secretary to issue regulations before completing PCAC consultation when necessary to protect public health. In principle that could be used to move faster. As of this writing, no such action has been announced.
It’s also worth being honest about what hasn’t changed at all. The substances reviewed here are not FDA-approved drugs, and nothing about the 2026 process would make them approved drugs. Even in the best case, they would become compoundable prescription substances - prepared by a licensed pharmacy for an individual patient under a valid prescription, with physician oversight. That’s a meaningful category, but it’s a different thing from approval, and the approved-drug list page explains the distinction.
What this means for you right now
If you’re reading this trying to figure out what’s actually available today, the practical picture is:
- Nothing about lawful access has flipped on. A pharmacy that wasn’t compounding these peptides in early 2026 has no new legal basis to start because of the Category 2 removal.
- The gray market hasn’t changed either. Peptides sold as “research use only” remain outside the patient-care framework - unverified purity, no sterility assurance, no oversight. The reclassification debate doesn’t make those products safer or more legal. We cover what that label really means on the research-use-only page.
- The legal route, if and when it opens, runs through a prescriber. That’s true today for the peptides that already have a lawful compounding basis, and it would be true for any of these 12 if they’re added to the bulks list. How that evaluation-to-prescription process works is laid out in how to get peptides prescribed.
In other words, the 2026 reclassification is important as a signal of where policy may be heading. It is not, by itself, a change you can act on.
What to watch next
Three dates and outcomes are the ones that actually move the needle:
July 23-24, 2026 - the PCAC vote.Done: six of seven recommended (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP rejected) - full results here.- FDA rulemaking after the vote. A recommendation is the start of a process, not the end. The signal to watch for is the FDA publishing a proposed rule that would actually add a substance to the 503A bulks list - that’s the next milestone now.
- Early 2027 - the second review. The remaining five peptides, including injectable GHK-Cu, are expected to be evaluated on a later timeline.
This page reflects the situation as of its last-updated date. Compounding regulation is moving quickly in 2026, and any of the above can change - so treat specific timing as provisional and verify the current status before relying on it. For the bigger-picture framework of how “legal” works across approved, compoundable, and research-only peptides, start with are peptides legal in the US.
Frequently asked questions
Did the FDA make peptides legal in 2026?
No. In April 2026 the FDA removed 12 peptides from Category 2 (its 'significant safety concerns' list), but it did not add any of them to Category 1, the list pharmacies can actually compound from. The July 2026 advisory committee vote recommended six of them - but that vote is nonbinding, and formal FDA rulemaking is still needed before legal compounding access changes.
Which peptides were removed from Category 2?
Twelve: BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, Emideltide (DSIP), LL-37 (Cathelicidin), DiHexa, PEG-MGF, Melanotan II, and injectable GHK-Cu. They came off the list because the parties that originally nominated them withdrew those nominations.
What happened at the July 23-24, 2026 PCAC meeting?
The Pharmacy Compounding Advisory Committee reviewed seven of the 12 peptides and voted to recommend six - BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon - for the 503A bulks list, rejecting only emideltide (DSIP). The votes were narrow, FDA's own scientists opposed all seven, and the recommendations are advisory: the FDA makes the final decision through rulemaking.
Can a compounding pharmacy legally make BPC-157 right now?
Not on the basis of the 2026 changes. Major pharmacy-law firms have advised clients not to treat the Category 2 removal as authorization. Until the FDA places a peptide on the Category 1 bulks list through a final rule, compounding it sits outside the agency's enforcement framework.
When could these peptides actually become legally compoundable?
The July committee did vote favorably on six peptides, so the question now is whether the FDA follows through with rulemaking - a proposed rule, public comment, then a final rule, with no deadline attached. Prior bulks-list rulemaking has taken over two years, so a realistic earliest window is late 2027 or beyond. Nothing is guaranteed - the vote is advisory and the FDA can decline.
Does this affect Ozempic, Wegovy, or compounded semaglutide?
No. The GLP-1 weight-loss drugs run on a completely different track (shortage lists and 503B rules), not the bulk-substance reclassification covered here. See the weight-loss pages for that story.